GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » 6-1 Month Momentum %

Santen Pharmaceutical Co (Santen Pharmaceutical Co) 6-1 Month Momentum % : 14.71% (As of Apr. 28, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-28), Santen Pharmaceutical Co's 6-1 Month Momentum % is 14.71%.

The industry rank for Santen Pharmaceutical Co's 6-1 Month Momentum % or its related term are showing as below:

SNPHY's 6-1 Month Momentum % is ranked better than
66.01% of 1112 companies
in the Drug Manufacturers industry
Industry Median: 3.415 vs SNPHY: 14.71

Competitive Comparison of Santen Pharmaceutical Co's 6-1 Month Momentum %

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's 6-1 Month Momentum % falls into.



Santen Pharmaceutical Co  (OTCPK:SNPHY) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co  (OTCPK:SNPHY) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Santen Pharmaceutical Co 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020